1. Scrip
  2. >>Business
  3. >>Deals

AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel

 
• By Joseph Haas

A week after bidding more than $10bn for ImmunoGen, AbbVie made one of 2023’s largest acquisitions again, this time betting big on Cerevel and its emraclidine for schizophrenia.

Big deal
AbbVie will pay $8.7bn for Cerevel to boost its neurology portfolio • Source: Shutterstock

AbbVie Inc. made a big splash in mergers and acquisitions for the second time in a week on 6 December, announcing an $8.7bn offer to acquire Cerevel Therapeutics Holdings, Inc. on the strength of its Phase II emraclidine for schizophrenia and potentially other neuropsychiatric indications. Together, the Cerevel buyout and the ImmunoGen, Inc. deal announced 30 November are two of the year’s four biggest biopharmaceutical M&A transactions and make the Chicago-area pharma the year’s second-biggest spender.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.